Ludger Dinkelborg, PhD
Director of the Board, Piramal Imaging SA
Managing Director, Piramal Imaging GmbH
Director of the Board, Piramal Imaging Ltd
Dr. Ludger Dinkelborg leads the Piramal Enterprises, Imaging Division, which was created through the acquisition of worldwide rights for the Molecular Imaging research and development portfolio of Bayer Pharma AG.
Before co-founding Piramal Imaging, Dr. Dinkelborg served as Head of Diagnostic Imaging Research and Head of Molecular Imaging at Bayer HealthCare. He brings more than 20 years of R&D experience in the pharmaceutical industry.
He received his PhD in biology at Heinrich-Heine-University, Düsseldorf, Germany and stayed as guest researcher at the Max-Planck-Institute for Molecular Physiology in Dortmund. He became a fellow of the Konrad-Adenauer-Foundation, attended the Cranfield Schering University course for managers, and the Stanford Executive Program, at Stanford School of Business, Stanford, CA.
Andrew Stephens, MD, PhD
Chief Medical Officer
Dr. Stephens has more than 20 years of experience in the pharmaceutical industry, primarily in the areas of oncology and diagnostic imaging. Previously, he was VP, Head Experimental Medicine Oncology/Diagnostic Imaging for Bayer Pharma. He has held positions of increasing responsibility at NeXagen/NeXstar, Gilead, Schering AG, and OSI Pharmaceuticals.
He received his BA cum laude in chemistry from the University of Colorado, Boulder. He also received an MD with honors and a PhD in biochemistry, biophysics and genetics from the University of Colorado, Boulder. Dr. Stephens is Board certified in Internal Medicine and had a clinical practice before entering pharmaceutical development.
Matthias Friebe, PhD
SVP Chemical R&D, Manufacturing and Control
Dr. Matthias Friebe is a co-founder of Piramal Imaging and heads the chemical research & development, manufacturing and control (CMC) departments.
Prior to Piramal Imaging, Dr. Friebe served as VP of Radiochemistry Research, Diagnostic Research at Bayer HealthCare. He has been contributing to the field of radiotherapy, SPECT- and PET-probe development for more than 18 years.
He studied Chemistry at the Technical University Dresden and received his PhD (Chemistry, Radiopharmaceutical Chemistry) at the Research Center Dresden-Rossendorf/Technical University Dresden. He held various positions at the Swiss Federal Institute of Technology (Dept. of Biopharmacy), Zurich, Switzerland and Harvard Medical School (Dept. of Radiology), Boston, MA, U.S.A. prior to joining Schering AG / Bayer HealthCare.
Susan De Santi, PhD
VP, Medical Affairs, North America and Asia Pacific
Dr. Susan De Santi is the VP of Medical Affairs for North America and Asia Pacific with six years of industry experience in diagnostic molecular imaging in both clinical development and Medical Affairs. Previously, she was the Global Medical Director, PET Neurology, Life Sciences, GE Healthcare and the Director, Global Clinical Development in Diagnostic Imaging at Bayer Healthcare Pharmaceuticals.
Susan was the 2015 Chairperson for the Private Partner Scientific Board of The Alzheimer’s Disease Neuroimaging Initiative (ADNI) and represents the interest of Piramal Imaging in other Alzheimer and Dementia Initiatives. She is a member of SNMMI and is on the Board of Directors of the Public Health Foundation Enterprises. Susan has co- authored more than 60 peer-reviewed articles, 10 book chapters and co-edited 1 book.
Prior to joining Piramal, Susan was an Associate Professor in the Department of Psychiatry, at New York University Langone Medical Center. In addition she was the Administrative Director at the Center for Brain Health and retains an adjunct Associate Professorship at this institution. She received her PhD from The Graduate School and University Center of CUNY with an emphasis in Neurolinguistics. Susan’s research focused on early diagnostic markers of mild cognitive impairment and Alzheimer’s disease using brain imaging (MRI, FDG and amyloid PET), biological markers, and cognition.
William F. Abbott
VP of Commercial Operations, North America and International
William F. Abbott is the Vice President, Operations for Piramal Imaging with overall accountability for commercial operations in the Americas.
Mr. Abbott has over thirty years of molecular imaging agent and device experience. He worked for DuPont Pharma (now Lantheus Medical Imaging) for 23 years serving in a diverse number of upper level management positions with responsibilities spanning manufacturing, customer service, distribution, marketing and business development functions. During his five-year tenure at Bracco Diagnostics, Inc. he served as Vice President of Operations and General Manager of Nuclear Medicine and was instrumental in repositioning Rb-82 as a clinically relevant myocardial perfusion imaging agent. As President of Jubilant Draximage, he served as chief executive officer of a $30M radiopharmaceuticals business directing all aspects of the business directing its aggressive global organic growth strategy and pipeline development of five concurrent projects.
Mr. Abbott has also served as chairmen of the board for Cardiac Imaging Solutions, CEO of a drug delivery platform start-up business and founded his own consulting business serving various clients within the molecular imaging industry.
VP of Commercial Operations, Northern Europe
Nico Beukman is the VP of Commercial Operations, Northern Europe at Piramal Imaging, and has served as the Director and Secretary to the Board of Piramal Imaging Limited for the past two years.
Mr. Beukman has more than 20 years of experience in the medical industry with a proven track record for managing strategic growth and execution of sales, marketing and commercial activities. Throughout his career, he has implemented creative and effective solutions for driving revenue growth and improving profitability while managing multinational teams.
Prior to Piramal Imaging, Mr. Beukman spent twelve years at Covidien now Mallinckrodt serving the company in various roles. Most recently, Mr. Beukman was the Vice President of Marketing for Pharmaceuticals and Imaging Solutions at Covidien. He was responsible for all marketing activities for sales in Europe, the Middle East and Africa for contrast media, devices, consumables and nuclear medicine product portfolios. Mr. Beukman earned his diploma in Clinical Engineering at Tswane University of Technology in South Africa.
VP of Commercial Operations, Southern Europe
Carlo Magni is the VP of Commercial Operations, Southern Europe for Piramal Imaging. In his role, Mr. Magni oversees multinational sales and marketing teams in France, Spain, Portugal, Slovenia, Malta, and Italy.
Mr. Magni has more than 35 years of experience in the medical industry, with specific in-depth experience in sales and marketing of high-technology diagnostic imaging equipment. Throughout his career, he has developed comprehensive global commercial strategies to effectively grow and manage large diagnostics portfolios in both domestic and international markets.
Prior to Piramal Imaging, Mr. Magni served as the National Sales Manager for AGFA Gevaert SpA Healthcare, and Sales Manager for PHILIPS where he was responsible for sales activity of the entire product portfolio of diagnostic imaging equipment. He has also served as a Marketing Manager for SIXCOM S.P.A. Olivetti Group, and a Product Manager for Siemens S.PA. Mr. Magni received his B.Sc. in Nuclear Engineering from Politecnico di Milano.
Head of Marketing, North America and International
Robert Sgroi has over 20 years of diversified experience in the field of Molecular Imaging. As a Board Certified and Registered Nuclear Medicine Technologist, Robert has combined his clinical experience and business acumen to support his passion for/to build a career centered around making a positive impact on the lives of patients, their families and those who care for them.
Prior to joining Piramal Imaging, Robert spent nearly 20 years at GE Healthcare. Robert‘s leadership roles at GE included Global Brand Director for a $350 million division of GE Healthcare and Brand Leader for DaTscan (Ioflupane I-123). DaTscan was the first significant molecular imaging agent to come to the US market in over a decade and the world’s first Schedule II radiopharmaceutical. As Brand Leader, he had sole responsibility for all aspects of the commercialization of this product including its 2009 U.S. launch.
Robert started his career with GE Healthcare as Senior Nuclear Medicine Technologist in the New York radiopharmacy. He was crossed trained in health physics and became the site Radiation Safety Officer. Robert also held positions in Clinical Research, Business Analytics and Brand Management. Robert holds a duel degree in both Business management and Nuclear Medicine.